A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN 002 (crofelmer) for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome

Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN 002 (crofelmer) for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2015

At a glance

  • Drugs Crofelemer (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2007 Results have been reported.
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top